DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The author estimates that in 2016, there were approximately 13,600 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 16,100 incident cases by 2025.
- It is estimated that the majority of diagnosed cases were in males in 2016. Approved drugs in the CTCL space target cluster of differentiation 30, histone deacetylase, retinoid receptors, DNA synthesis, interleukin-2, and protein synthesis. These drugs are administered via the intravenous, topical, and oral routes.
- Half of all industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only two drugs in Phase III. Therapies in mid-to-late-stage development for CTCL focus on a wide variety of targets, with the majority administered via the intravenous route.
- High-impact upcoming events include topline Phase II and Phase III trial results for resminostat and SGX301, as well as the end of Phase II meeting with the FDA for remetinostat.
- There were 14 licensing and asset acquisition activities involving CTCL drugs during 2012-17. The exclusive acquisition agreement signed in 2016 between Medivir AB and Tetralogic Pharmaceuticals for $238m for the acquisition of two clinical stage oncology programs was the largest deal during the period.
- Istodax's US parent patents (polymorph, process, and composition) are set to expire in August 2021, which will open the door to generic entries.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CTCL have been in the early and midphases of development, with 86% of trials in Phase I-II, and only 14% in Phase III-IV.
- The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the CTCL space is dominated by completed trials. Merck & Co, Ligand, and Takeda have the highest number of completed clinical trials for CTCL, with five completed trials each. Meanwhile, Celgene has six ongoing trials.
- Celgene leads industry sponsors with the highest number of clinical trials for CTCL, followed by Merck & Co and Seattle Genetics.
Key Topics Covered:
Approvals by country
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
Sponsors by status
Sponsors by phase
For more information about this report visit https://www.researchandmarkets.com/research/6w9whh/10_year_cutaneous?w=4